Acute Lymphoblastic Leukemia

Rituximab with stem cell autografts effective after relapse

Published in Cancer Weekly, June 17th, 2003

In combination with stem cell autotransplantation, the monoclonal antibody rituximab is effective for children with relapsed acute lymphoblastic leukemia (ALL).

"Childhood B-cell neoplasms account for approximately 2%" of pediatric ALL cases, scientists in Switzerland explained. "The short but intensive chemotherapy yields a currently 75% to 85% event-free survival."

However, "the prognosis for children with relapsed disease is considered to be dismal," according to S. Corbacioglu and coauthors at the University of Zurich, who described their experience with "a 12-year old boy diagnosed with B-cell ALL with central nervous system (CNS)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-06-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry